Outcomes That Last

lockup1a

Bausch + Lomb

AN OPPORTUNITY OF A LIFETIME

Moving beyond yesterday’s expectations to meet the needs of today’s cataract patients

Cataract surgery is an opportunity to give your patients vision for their life ahead. True to that, Bausch + Lomb’s innovative technologies focus on long term vision that can help you achieve outstanding outcomes and continued practice success.

Cataract Patients

Long Term Vision for your patients

Achieve consistently excellent long term results

Click on any of the products below to learn more.

button-down

victus-icon

VICTUS®

Femtosecond Laser Platform

stellaris-icon

Stellaris® PC

Vision Enhancement System

crystalens-icon

Crystalens® AO

Accommodating IOL

envista-icon

Envista®

Hydrophobic Acrylic IOL

trulign-icon

Trulign® Toric

Posterior Chamber IOL

victus-text

Best-In-Class Intraoperative Precision And Control

  • Dual-Modality Performance optimizes precision for both corneal and cataract applications
  • Exclusive live-action OCT provides advanced visualization from start to finish
  • High pulse rate and small spot size for accuracy and consistency
  • Intelligent Pressure Sensors enable procedure-optimized downward pressure
victus-big
stellaris-text

Control Lens Removal With Advanced Phaco Technology

  • Outstanding chamber stability and control with vacuum-based StableChamber® fluidics1
  • Dual-linear wireless footpedal with laser activation button
  • Maximized efficiency with Attune® Energy Management System
  • Options for zero ultrasound, femto-treated lens removal
stellaris-big
crystalens-text

An Active Range Of Vision That Matters Most To Today’s Presbyopes

  • Deliver an active range of vision with acuity compared to multifocals
  • Achieve better contrast sensitivity2, 3 by focusing 100% of light, 100% of the time
  • Minimize issues with neuroadaptation, halos, and glare2, 3
  • Excellent distance, intermediate, and near visual outcomes sustained up to 7 years in a sub-study of patients4
crystalens-big
envista-text

Long Term Clarity And Quality Of Vision With Advanced Optics

  • No glistenings were reported at any time in controlled clinical studies5
  • AO optics = LARGER SWEET SPOT!
    • Aberration-free optic is designed to deliver contrast without compromising depth of field6
    • The optic is less sensitive to misalignment or decentration6, 7
  • Potential for increased resistance to scratches or abrasions8
envista-big
trulign-text

A Broader Range Of Vision For Astigmatic Correction

  • A broader range of vision than any standard toric IOL9-12
  • Excellent visual acuity at intermediate and distance13
  • Outstanding rotational stability, effective cylinder correction, and precise refractive predictability13
  • 99.2% of patients reported no significant visual disturbances13
trulign-big

Premium Vision

Long Term Vision for your practice

Building toward a stronger future together

  • Leading premium vision offerings with supporting programs, patient education, and specialist teams to drive practice revenue opportunities
  • Continuous focused innovation through R&D to deliver meaningful visual outcomes and added technology efficiency
  • Clinical and practice education to optimize outcomes
  • Practice support to drive efficiency and effectiveness

CONNECT WITH A REP

Please complete the form below and a representative will contact you. (* required field)

  • This field is for validation purposes and should be left unchanged.

Important Safety Information:

VICTUS® Femtosecond Laser Platform

isi1

CAUTION: United States Federal Law restricts this device to sale and use by or on the order of a licensed physician. INDICATIONS: The VICTUS Platform is indicated for use in the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea, for anterior capsulotomy during cataract surgery, the creation of cuts/incisions in the cornea in patients undergoing cataract surgery or other ophthalmic treatment requiring cuts/incisions in the cornea, and for laser-assisted lens fragmentation during cataract surgery for nuclear cataracts, not for fragmentation of posterior subcapsular (PSC) and cortical cataracts. Attention: Please refer to the Directions for Use for complete use instructions and safety. SUMMARY OF CONTRAINDICATIONS: Corneal disease or pathology that precludes transmission of laser wavelength or distortion of laser light. Patients who do not give informed consent, who are pregnant or nursing, have existing corneal implants, who have had any previous cornea surgery or pediatric patients. Conditions that interfere with intent to treat such as glaucoma, retinal disorders, rheumatic diseases, epilepsy, herpes zoster or herpes simplex keratitis, and heavy vascularization of ocular tissues. Conditions that interfere with proper docking such as chemosis, nystagmus, significant loss of stability of the conjunctiva, keratoconus, and corneal diseases requiring treatment. Conditions that may interfere with capsulotomy such as poorly dilating pupils, and anterior chamber depths (ACD) < 1.5 mm or ACD > 4.8 mm. Conditions that may interfere with creation of flap such as dry eye diseases, cataract, diabetes mellitus, severe acne rosacea, severe wound healing disorders, and immune deficiency diseases. Contraindicated for laser-assisted lens fragmentation of posterior subcapsular (PSC) and cortical cataracts.

Stellaris® PC Vision Enhancement System

Crystalens® AO Accommodating IOL

INDICATIONS FOR USE: The Crystalens is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia secondary to the removal of a cataractous lens in adult patients with and without presbyopia. The Crystalens provides approximately one diopter of monocular accommodation which allows for near, intermediate, and distance vision without spectacles. WARNINGS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient. Some adverse events which have been associated with the implantation of intraocular lenses are: hypopyon, intraocular infection, acute corneal decompensation, and secondary surgical intervention. PRECAUTIONS: Do not resterilize; do not store over 45°C. ATTENTION: Refer to the Physician Labeling for complete prescribing information.

TRULIGN® Toric Posterior Chamber IOL

INDICATIONS FOR USE: The TRULIGN Toric Posterior Chamber Intraocular Lens is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia and postoperative refractive astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia who desire reduction of residual refractive cylinder with increased spectacle independence and improved uncorrected near, intermediate and distance vision. WARNINGS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient. Some adverse events which have been associated with the implantation of intraocular lenses are: hypopyon, intraocular infection, acute corneal decompensation, and secondary surgical intervention. SAFETY AND PRECAUTIONS: Do not resterilize; do not store over 45°C. ATTENTION: Please see Directions For Use for important safety information.

enVista® Hydrophobic Acrylic IOL

The enVista IOL is indicated for primary implantation for the visual correction of aphakia in adult patients in whom the cataractous lens has been removed. The lens is intended for placement in the capsular bag. Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: 1. Severe anterior or posterior segment inflammation or uveitis. 2. Patients in whom the intraocular lens may affect the ability to observe, diagnose, or treat posterior segment diseases. 3. Surgical difficulties that increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss). 4. Any trauma or developmental defect in which appropriate support of the IOL is not possible. 5. Circumstances that would result in damage to the endothelium during implantation. 6. Suspected microbial infection. 7. Children under the age of 2 years are not suitable candidates . 8. Patients in whom neither the posterior capsule nor zonules are intact enough to provide support. The safety and effectiveness of the enVista IOL have not been substantiated in patients with preexisting ocular conditions and intraoperative complications. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting a lens in a patient with one or more these conditions; vitreous loss (significant), anterior chamber bleeding (significant), uncontrollable positive intraocular pressure. Patients with preoperative problems such as corneal endothelial disease, abnormal cornea, macular degeneration, retinal degeneration, glaucoma, and chronic drug miosis may not achieve the visual acuity of patients without such problems. Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, transient or persistent glaucoma, and secondary surgical intervention. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair. For a complete storage and handling information and for physician labeling information, refer to the enVista product package insert.

References:

  1. Data on file, Bausch & Lomb. Study 521.
  2. Ang R, Martinez G, Cruz E, Tiongson A, Dela Cruz A. Prospective evaluation of visual outcomes with three presbyopia-correcting intraocular lenses following cataract surgery. Clin Ophthalmol. 2013;7:1811-23. doi: 10.2147/OPTH.S49848.
  3. Pepose JS, Qazi MA, Davies J, et al. Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants. Am J Ophthalmol. 2007;144(3):347-357.
  4. Colvard DM. Long-term stability of accommodative IOLs. Ophthalmol Manage. 2011;Aug(suppl):13-15.
  5. Bausch & Lomb Incorporated Study #658 – “A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of a Bausch + Lomb One Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction.” Final Clinical Study Report, dated 24 Aug 2011.
  6. Altmann GE, Edwards KH. The aberration-free IOL: Advanced optical performance independent of patient profile. Presented at: 2004 Symposium on Cataract, IOL, and Refractive Surgery; May 1-5, 2004; San Diego, CA.
  7. Altmann GE, Nichamin LD, Lane SS, Pepose JS. Optical performance of 3 intraocular lens designs in the presence of decentration. J Cataract Refract Surg. 2005;31(3):574-585.
  8. Mentak K, Martin P, Elachchabi A, Goldberg E. Nanoindentation studies on hydrophobic acrylic IOLs to evaluate surface mechanical properties. Paper presented at: XXV Congress of the European Society of Cataract & Refractive Surgeons (ESCRS); September 8-12, 2007; Stockholm, Sweden.
  9. TRULIGN® Toric IOL Directions for Use.
  10. AcrySof Toric IOL Directions for Use.
  11. TECNIS Toric IOL Directions for Use.
  12. Staar Toric IOL Directions for Use.
  13. Data on file, Bausch & Lomb Incorporated. Study 650.

© 2015 Bausch & Lomb Incorporated.
SUR/SRG/15/0038

Log in with your credentials

Forgot your details?